Capstan Therapeutics Announces up to $2.1 Billion Acquisition by AbbVie
San Diego – June 30, 2025 – Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie. AbbVie will acquire Capstan, including CPTX2309 – a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 chimeric antigen receptor T-cell therapy candidate currently in Phase 1 for treating B cell-mediated autoimmune disease – as well as Capstan’s proprietary tLNP platform technology, which delivers RNA payloads, such as messenger RNA (mRNA), to engineer specific cell types in vivo. Under the terms of the agreement, AbbVie will pay up to $2.1 billion in cash at closing, subject to certain customary adjustments.
Lawyers Rama Padmanabhan, Ken Rollins, Edmond Lay, Charity Williams and Lindsey O’Crump led the Cooley team advising Capstan.
Cooley previously advised Capstan on its $175 million oversubscribed Series B in March 2024.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may have been generated with the assistance of artificial intelligence (AI) in accordance with our AI Principles, may be considered Attorney Advertising and is subject to our legal notices.